Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
Moustafa Abdou, Author and Founder of AskHematologist.com, shared a post on LinkedIn:
”Cold Agglutinin Disease (CAD)
Cold Agglutinin Disease is a rare but clinically significant complement-mediated autoimmune hemolytic anemia driven by cold-reactive IgM antibodies.
What makes CAD particularly important is its dual presentation: chronic hemolysis alongside cold-induced circulatory symptoms such as acrocyanosis and Raynaud-like changes.
Diagnosis requires a high index of suspicion, with a characteristic C3d-positive direct antiglobulin test and evidence of complement activation.
Management has evolved significantly in recent years.
While cold avoidance and rituximab-based therapy remain important, targeted complement inhibition (e.g. sutimlimab) is transforming outcomes in selected patients.
Early recognition is key to preventing complications and improving quality of life.”
Stay updated with Hemostasis Today.
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership
-
May 31, 2026, 14:31Mirjam Teboe: The Golden Rule Behind Reliable Lupus Anticoagulant Testing
-
May 31, 2026, 14:20Improving Access to Care for People Living with Haemophilia and Haemoglobinopathies – NNHF